Durvalumab plus gemcitabine/cisplatin/nab-paclitaxel in resectable biliary tract cancer: A phase II, single-arm, open-label study (DurGAP). This is an ASCO Meeting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results